HK1251567A1 - Heteroaryl compounds for kinase inhibition - Google Patents

Heteroaryl compounds for kinase inhibition

Info

Publication number
HK1251567A1
HK1251567A1 HK18111064.8A HK18111064A HK1251567A1 HK 1251567 A1 HK1251567 A1 HK 1251567A1 HK 18111064 A HK18111064 A HK 18111064A HK 1251567 A1 HK1251567 A1 HK 1251567A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibition
heteroaryl compounds
heteroaryl
compounds
kinase
Prior art date
Application number
HK18111064.8A
Other languages
Chinese (zh)
Inventor
Tianjun Zhou
Willmen W Youngsaye
William C Shakespeare
Alexey V Ishchenko
Wei-Sheng Huang
David C Dalgarno
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of HK1251567A1 publication Critical patent/HK1251567A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK18111064.8A 2015-05-13 2018-08-28 Heteroaryl compounds for kinase inhibition HK1251567A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160989P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
HK1251567A1 true HK1251567A1 (en) 2019-02-01

Family

ID=57249337

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111064.8A HK1251567A1 (en) 2015-05-13 2018-08-28 Heteroaryl compounds for kinase inhibition

Country Status (5)

Country Link
US (1) US20210323976A1 (en)
EP (1) EP3294712A4 (en)
JP (1) JP6863901B2 (en)
HK (1) HK1251567A1 (en)
WO (1) WO2016183278A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501612B (en) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 The compound that cell is bred in cancer caused by suppression EGF-R ELISA
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN108299419B (en) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 Novel crystal forms of novel EGFR kinase inhibitor and preparation method thereof
CN109705117A (en) * 2017-10-25 2019-05-03 南京圣和药业股份有限公司 Tricyclic compounds, preparation method and the usage
CN109705118B (en) * 2017-10-25 2021-12-28 南京圣和药业股份有限公司 Preparation method of tricyclic EGFR kinase inhibitor
CN108191861B (en) * 2018-03-01 2020-10-02 天津大学 N- [5- (pyrimidin-2-amino) -2, 4-disubstituted-phenyl ] -trans-2, 4-pentadiene-amide
AU2020296620B2 (en) * 2019-06-20 2023-07-13 Oncobix Co.Ltd. Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
US20230131720A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
JP2023512174A (en) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング [1,3]diazino[5,4-d]pyrimidines as HER2 inhibitors
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
CN112409192A (en) * 2020-11-26 2021-02-26 启东东岳药业有限公司 Purification method of 4-fluoro-2-methoxyaniline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000251A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel idolinones and uses thereof
CA2920996A1 (en) * 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
LT2300013T (en) * 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) * 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101892989B1 (en) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 Heteroaryl compounds and uses thereof
ES2900230T3 (en) * 2011-07-27 2022-03-16 Astrazeneca Ab 2-(2,4,5-anilino substituted)pyrimidine compounds
AU2014337067B2 (en) * 2013-10-18 2019-01-24 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3143015B1 (en) * 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
DK3157916T3 (en) * 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
CN107614503B (en) * 2015-04-29 2020-03-10 广东众生药业股份有限公司 Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors

Also Published As

Publication number Publication date
US20210323976A1 (en) 2021-10-21
JP2018515514A (en) 2018-06-14
WO2016183278A1 (en) 2016-11-17
EP3294712A4 (en) 2018-11-07
EP3294712A1 (en) 2018-03-21
JP6863901B2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
IL274159A (en) Heteroaryl compounds for kinase inhibition
HUS2400003I1 (en) Compounds useful as kinase inhibitors
IL259719A (en) Tank-binding kinase inhibitor compounds
EP3143015A4 (en) Heteroaryl compounds for kinase inhibition
HK1251567A1 (en) Heteroaryl compounds for kinase inhibition
IL255750A (en) Heterocyclic compounds as kinase inhibitors
IL266789A (en) Heterocyclic compounds as kinase inhibitors
HK1249901B (en) Compounds useful for inhibiting ror-gamma-t
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors